Annual EBITDA
-$6.86 M
-$4.54 M-196.02%
December 31, 2023
Summary
- As of February 7, 2025, CHRO annual EBITDA is -$6.86 million, with the most recent change of -$4.54 million (-196.02%) on December 31, 2023.
- During the last 3 years, CHRO annual EBITDA has fallen by -$6.20 million (-941.48%).
- CHRO annual EBITDA is now -1053.13% below its all-time high of -$595.10 thousand, reached on December 1, 2021.
Performance
CHRO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$2.02 M
-$258.17 K-14.66%
September 30, 2024
Summary
- As of February 7, 2025, CHRO quarterly EBITDA is -$2.02 million, with the most recent change of -$258.17 thousand (-14.66%) on September 30, 2024.
- Over the past year, CHRO quarterly EBITDA has increased by +$1.86 million (+47.96%).
- CHRO quarterly EBITDA is now -861.30% below its all-time high of -$210.00 thousand, reached on December 1, 2021.
Performance
CHRO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$9.59 M
-$727.03 K-8.20%
September 30, 2024
Summary
- As of February 7, 2025, CHRO TTM EBITDA is -$9.59 million, with the most recent change of -$727.03 thousand (-8.20%) on September 30, 2024.
- Over the past year, CHRO TTM EBITDA has dropped by -$2.73 million (-39.78%).
- CHRO TTM EBITDA is now -4467.66% below its all-time high of -$210.00 thousand, reached on December 1, 2021.
Performance
CHRO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CHRO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -196.0% | +48.0% | -39.8% |
| 3 y3 years | -941.5% | -289.1% | -630.4% |
| 5 y5 years | -941.5% | -289.1% | -630.4% |
CHRO EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -1053.1% | at low | -861.3% | +48.0% | -4467.7% | at low |
| 5 y | 5-year | -1053.1% | at low | -861.3% | +48.0% | -4467.7% | at low |
| alltime | all time | -1053.1% | at low | -861.3% | +48.0% | -4467.7% | at low |
Chromocell Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.02 M(+14.7%) | -$9.59 M(+8.2%) |
| Jun 2024 | - | -$1.76 M(-9.0%) | -$8.87 M(+12.5%) |
| Mar 2024 | - | -$1.93 M(-50.1%) | -$7.88 M(+14.9%) |
| Dec 2023 | -$6.86 M | -$3.88 M(+200.3%) | -$6.86 M(+63.5%) |
| Sep 2023 | - | -$1.29 M(+66.2%) | -$4.20 M(+22.6%) |
| Jun 2023 | - | -$777.20 K(-15.0%) | -$3.43 M(+16.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$914.60 K(-24.7%) | -$2.94 M(+27.0%) |
| Dec 2022 | -$2.32 M(+289.5%) | -$1.21 M(+134.2%) | -$2.32 M(+76.5%) |
| Sep 2022 | - | -$518.80 K(+74.9%) | -$1.31 M(+65.3%) |
| Jun 2022 | - | -$296.70 K(+3.1%) | -$794.50 K(+59.6%) |
| Mar 2022 | - | -$287.80 K(+37.0%) | -$497.80 K(+137.0%) |
| Dec 2021 | -$595.10 K(-9.7%) | -$210.00 K | -$210.00 K |
| Dec 2020 | -$658.90 K | - | - |
FAQ
- What is Chromocell Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Chromocell Therapeutics?
- What is Chromocell Therapeutics annual EBITDA year-on-year change?
- What is Chromocell Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Chromocell Therapeutics?
- What is Chromocell Therapeutics quarterly EBITDA year-on-year change?
- What is Chromocell Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Chromocell Therapeutics?
- What is Chromocell Therapeutics TTM EBITDA year-on-year change?
What is Chromocell Therapeutics annual EBITDA?
The current annual EBITDA of CHRO is -$6.86 M
What is the all time high annual EBITDA for Chromocell Therapeutics?
Chromocell Therapeutics all-time high annual EBITDA is -$595.10 K
What is Chromocell Therapeutics annual EBITDA year-on-year change?
Over the past year, CHRO annual EBITDA has changed by -$4.54 M (-196.02%)
What is Chromocell Therapeutics quarterly EBITDA?
The current quarterly EBITDA of CHRO is -$2.02 M
What is the all time high quarterly EBITDA for Chromocell Therapeutics?
Chromocell Therapeutics all-time high quarterly EBITDA is -$210.00 K
What is Chromocell Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CHRO quarterly EBITDA has changed by +$1.86 M (+47.96%)
What is Chromocell Therapeutics TTM EBITDA?
The current TTM EBITDA of CHRO is -$9.59 M
What is the all time high TTM EBITDA for Chromocell Therapeutics?
Chromocell Therapeutics all-time high TTM EBITDA is -$210.00 K
What is Chromocell Therapeutics TTM EBITDA year-on-year change?
Over the past year, CHRO TTM EBITDA has changed by -$2.73 M (-39.78%)